Celcuity (NASDAQ:CELC) Given Market Outperform Rating at Citizens Jmp

Celcuity (NASDAQ:CELC)‘s stock had its “market outperform” rating reissued by equities research analysts at Citizens Jmp in a note issued to investors on Monday,Benzinga reports. They presently have a $177.00 price objective on the stock. Citizens Jmp’s target price points to a potential upside of 92.39% from the company’s current price.

Other analysts have also issued research reports about the company. Macquarie Infrastructure set a $160.00 price objective on Celcuity in a report on Thursday, May 28th. Craig Hallum reaffirmed a “buy” rating and set a $178.00 price target on shares of Celcuity in a research report on Wednesday, July 15th. Needham & Company LLC lowered their price objective on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright restated a “buy” rating and set a $155.00 target price on shares of Celcuity in a research report on Friday. Finally, Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $153.64.

Celcuity Stock Performance

Shares of CELC stock opened at $92.00 on Monday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a 50 day moving average price of $93.88 and a 200-day moving average price of $108.41. Celcuity has a 52 week low of $44.42 and a 52 week high of $151.02. The firm has a market capitalization of $4.49 billion, a PE ratio of -21.40 and a beta of 0.21.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). As a group, equities research analysts expect that Celcuity will post -3.76 earnings per share for the current year.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently modified their holdings of CELC. Artia Global Partners LP bought a new position in Celcuity in the 2nd quarter worth $6,206,000. Bank of America Corp DE purchased a new position in shares of Celcuity in the second quarter valued at about $153,928,000. Freestone Grove Partners LP bought a new position in shares of Celcuity in the second quarter worth about $7,104,000. Man Group plc purchased a new stake in shares of Celcuity during the second quarter worth about $3,018,000. Finally, Jupiter Topco LLC bought a new stake in Celcuity during the 2nd quarter valued at approximately $754,000. 63.33% of the stock is currently owned by institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.